CureVac's Phase IIb/III COVID-19 vaccine trial begins

14 December 2020

Messenger ribonucleic acid (mRNA) specialist company CureVac (Nasdaq: CVAC) has enrolled the first participant in the pivotal Phase IIb/III study of its vaccine candidate, CVnCoV, against COVID-19.

The randomized, observer blind, placebo-controlled Phase IIb/III trial called HERALD will assess the safety and efficacy of CVnCoV in adults at a dose of 12µg. The study is expected to include more than 35,000 participants at sites in Europe and Latin America.

Franz-Werner Haas, chief executive of CureVac, said: “With the start of the pivotal Phase IIb/III study, we have reached another important milestone in the development of our vaccine candidate, CVnCoV.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK